Abstract
Histone deacetylases (HDACs), as epigenetic modifiers, are essential for gene transcriptional activities. The alternation of HDACs expression, mutation and/or inappropriate recruitments has been discovered in a broad range of tumors contributing to the tumorigenesis through a serial of biological pathways. HDACs, therefore, are characterized as promising cancer therapeutic targets, and their inhibitors are under rapid development. Here, we discuss HDAC inhibitors in terms of their functional mechanism establishing the anti-tumor effects and potential clinical applications including the synergistic effects in combinational treatment.
Keywords: Histone Deacetylase, Inhibitors, Epigenetics, Cancer treatment, RNA, DNA.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Histone Deacetylase Inhibitors in Cancer Therapy
Volume: 18 Issue: 28
Author(s): Yijie Sun, Yanyi Sun, Saichao Yue, Yaohe Wang and Fanghui Lu*
Affiliation:
- National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou,China
Keywords: Histone Deacetylase, Inhibitors, Epigenetics, Cancer treatment, RNA, DNA.
Abstract: Histone deacetylases (HDACs), as epigenetic modifiers, are essential for gene transcriptional activities. The alternation of HDACs expression, mutation and/or inappropriate recruitments has been discovered in a broad range of tumors contributing to the tumorigenesis through a serial of biological pathways. HDACs, therefore, are characterized as promising cancer therapeutic targets, and their inhibitors are under rapid development. Here, we discuss HDAC inhibitors in terms of their functional mechanism establishing the anti-tumor effects and potential clinical applications including the synergistic effects in combinational treatment.
Export Options
About this article
Cite this article as:
Sun Yijie, Sun Yanyi , Yue Saichao , Wang Yaohe and Lu Fanghui *, Histone Deacetylase Inhibitors in Cancer Therapy, Current Topics in Medicinal Chemistry 2018; 18 (28) . https://dx.doi.org/10.2174/1568026619666181210152115
DOI https://dx.doi.org/10.2174/1568026619666181210152115 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review
Current Genomics Updates of mTOR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry 2-Deoxy-D-Ribose, a Downstream Mediator of Thymidine Phosphorylase, Regulates Tumor Angiogenesis and Progression
Anti-Cancer Agents in Medicinal Chemistry Pulmonary Drug Delivery System: A Novel Approach for Drug Delivery
Current Drug Therapy Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine
Current Drug Metabolism Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment
Current Medicinal Chemistry Cancer Chemoprevention by Dietary Phytochemicals: Promises and Pitfalls
Current Pharmaceutical Biotechnology PEGylated Peptide-Based Imaging Agents for Targeted Molecular Imaging
Current Protein & Peptide Science Secondary Radiation-Induced Bone Tumours Demonstrate a High Degree of Genomic Instability Predictive of a Poor Prognosis
Current Genomics Development of Patents and Clinical Trials on Regenerative Therapy: Gene Therapy
Recent Patents on Regenerative Medicine Acyl Thiourea Derivatives Containing Pyrazole Ring Selective Targeting of Human Aurora Kinases in Breast and Bone Cancer
Letters in Drug Design & Discovery The Promise of miRNA Replacement Therapy for Hepatocellular Carcinoma
Current Gene Therapy The Role of Proteomics in Osteoarthritis Pathogenesis Research
Current Drug Targets CD95 Signaling in Cancer Treatment
Current Pharmaceutical Design The Influence of DNA Methylation on Bone Cells
Current Genomics Advances in the Use of Stem Cells and Tissue Engineering Applications in Bone Repair
Current Stem Cell Research & Therapy Neuropilin and Neuropilin Associated Molecules as New Molecular Targets in Pancreatic Adenocarcinoma
Anti-Cancer Agents in Medicinal Chemistry